Klausner J M, Morel N, Paterson I S, Kobzik L, Valeri C R, Eberlein T J, Shepro D, Hechtman H B
Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115.
Ann Surg. 1989 Jan;209(1):119-28. doi: 10.1097/00000658-198901000-00017.
The clinical use of interleukin-2 (IL-2) is limited by severe cardiopulmonary dysfunction. This study examines the mechanism of respiratory failure related to IL-2, using sheep with chronic lung lymph fistulae. Awake animals were infused with an intravenous (I.V.) bolus of IL-2 10(5) U/kg (n = 5) or its excipient (EXC) control (n = 3), every 8 hours for 4 to 5 days. Cardiopulmonary function was monitored daily for at least one 8-hour period. Within 2 hours after each IL-2 administration, mean pulmonary arterial pressure (MPAP) rose. On Day 1, the mean rise was from 13 to 26 mmHg (p less than 0.05), and on Day 5, to 29 mmHg (p less than 0.05). MPAP returned to baseline levels after 2-3 hours. Pulmonary arterial wedge pressure was unchanged from 4 mmHg. There were transient falls in arterial oxygen tension, from 88 to 77 mmHg on Day 1 and to 73 mmHg (p less than 0.05) on Day 5. Lung lymph flow (QL) rose from 2.4 to 6.8 ml/30 minutes (p less than 0.05) on Day 1, and from 4.7 to 10.2 ml/30 minutes (p less than 0.05) on Day 5, whereas the lymph/plasma protein ratio increased on Day 1 from 0.69 to 0.83 (p less than 0.05) and from 0.63 to 0.71 (p less than 0.05) on Day 5. This documents an increase in pulmonary microvascular permeability. Thromboxane (Tx)B2 levels increased transiently after each IL-2 injection in plasma from 195 to 340 pg/ml (p less than 0.05) and in lung lymph from 222 to 772 pg/ml (p less than 0.05) on Day 1, and to similar levels on Day 5. There was a progressive rise in cardiac output from 5.7 to 8.6 1/minute (p less than 0.05) during the 5 days of infusion. Systemic blood pressure did not change. Temperature rose from 39.1 to 41.2 C (p less than 0.05), and shaking chills were common. There was a progressive fall in leukocyte count, from 8.4 to 3.2 X 10(3)/mm3 (p less than 0.05) by Day 5, reflecting a 77% fall in lymphocytes. Lung lymph lymphocyte counts rose, and lymphocyte clearance increased.(ABSTRACT TRUNCATED AT 250 WORDS)
白细胞介素-2(IL-2)的临床应用受到严重心肺功能障碍的限制。本研究利用患有慢性肺淋巴瘘的绵羊,探讨与IL-2相关的呼吸衰竭机制。对清醒动物每8小时静脉推注10⁵U/kg的IL-2(n = 5)或其赋形剂(EXC)对照物(n = 3),持续4至5天。每天至少监测一次心肺功能,为期8小时。每次给予IL-2后2小时内,平均肺动脉压(MPAP)升高。第1天,平均升高幅度从13 mmHg升至26 mmHg(p<0.05),第5天升至29 mmHg(p<0.05)。2 - 3小时后MPAP恢复至基线水平。肺动脉楔压维持在4 mmHg不变。动脉血氧张力出现短暂下降,第1天从88 mmHg降至77 mmHg,第5天降至73 mmHg(p<0.05)。肺淋巴流量(QL)在第1天从2.4 ml/30分钟升至6.8 ml/30分钟(p<0.05),第5天从4.7 ml/30分钟升至10.2 ml/30分钟(p<0.05),而淋巴/血浆蛋白比值在第1天从0.69升至0.83(p<0.05),第5天从0.63升至0.71(p<0.05)。这证明肺微血管通透性增加。每次注射IL-2后,血浆中血栓素(Tx)B₂水平短暂升高,第1天从195 pg/ml升至340 pg/ml(p<0.05),肺淋巴中从222 pg/ml升至772 pg/ml(p<0.05),第5天升至相似水平。在输注的5天中,心输出量逐渐从5.7升/分钟升至8.6升/分钟(p<0.05)。体循环血压未改变。体温从39.1℃升至41.2℃(p<0.05),寒战常见。白细胞计数逐渐下降,到第5天从8.4×10³/mm³降至3.2×10³/mm³(p<0.05),淋巴细胞减少77%。肺淋巴中淋巴细胞计数升高,淋巴细胞清除增加。(摘要截选至250字)